Clinical trialCLINICALTRIALSMar 31
Researchers are building a large international database to collect information and tissue samples from children, teens, and young adults with rare brain tumors. By gathering this data from 5,800 patients, scientists hope to better understand these uncommon cancers and develop better treatments. The study is currently looking for patients to participate.
WHY IT MATTERSThis registry directly addresses rare brain tumors like astroblastoma and BCOR ITD sarcoma that have limited research data—participating patients contribute to the only large-scale international effort to understand these specific tumor types.
Clinical trialCLINICALTRIALSMar 27
Researchers are testing a cancer drug called trastuzumab deruxtecan (T-DXd) in patients with several types of rare and uncommon cancers that have a specific protein marker called HER2. The study includes seven different cancer types in the first part, including bladder, bile duct, cervical, uterine, ovarian, and pancreatic cancers. This drug has already shown promise in breast and stomach cancers, and doctors want to see if it works in these other cancer types too.
WHY IT MATTERSThis trial offers patients with HER2-positive rare cancers like biliary tract, cervical, endometrial, ovarian, and pancreatic cancer access to a targeted therapy that has demonstrated effectiveness in other cancer types—potentially providing a new treatment option where few exist.
Clinical trialCLINICALTRIALSMar 27
Researchers are testing a new combination treatment for metastatic Merkel cell carcinoma, a rare type of skin cancer. The study combines a drug called avelumab with either a radioactive therapy or radiation treatment. The trial is currently enrolling patients and aims to see if this combination is safe and effective at fighting the cancer.
WHY IT MATTERSThis trial offers patients with metastatic Merkel cell carcinoma access to a novel combination therapy that may provide additional treatment options beyond standard care, though enrollment is currently closed.
PolicyPUBMEDMar 26
France is creating a new type of healthcare worker called a Genomic Pathway Manager to help doctors order genetic tests for patients with rare diseases and cancer. These managers will make it easier for patients to get genetic testing by organizing the process and helping doctors understand when and how to use these tests. The goal is to make genetic testing available to more people across France starting in 2025.
WHY IT MATTERSIf you have a rare disease in France, this new system could help your doctor identify your condition faster through genetic testing, potentially leading to earlier diagnosis and treatment options.
ResearchPUBMEDMar 26
Scientists are developing tiny particles called exosomes that can deliver cancer-fighting medicines directly to rare cancer tumors. These natural particles act like delivery trucks, carrying drugs to cancer cells while reducing damage to healthy cells. Early research shows this approach could help rare cancer patients who currently have few treatment options.
WHY IT MATTERSPatients with rare cancers often lack targeted treatments and face delayed diagnoses—exosome-based therapies could provide new options by delivering drugs more effectively to tumors while causing fewer side effects.
ResearchPUBMEDMar 26
Researchers in China studied 26 children and young adults (average age 8 years old) who had a rare cancer called rhabdomyosarcoma that started in the female reproductive organs. They tracked these patients for an average of nearly 5 years to see how well different treatments worked. This study helps doctors understand the best ways to treat this uncommon type of cancer in girls and young women.
WHY IT MATTERSThis is the first large study from China showing long-term survival rates for girls with genital rhabdomyosarcoma, which can help doctors worldwide improve treatment plans and give families more accurate information about what to expect.
ResearchPUBMEDMar 26
Doctors found a very rare type of cancer in a woman's urethra (the tube that carries urine out of the body). This cancer, called clear cell adenocarcinoma, is so uncommon that only a few cases have ever been reported. The article describes how doctors used special imaging scans (MRI and PET/CT) to find and diagnose this cancer.
WHY IT MATTERSThis case report helps doctors recognize and diagnose primary clear cell adenocarcinoma of the female urethra earlier, since it's so rare that many physicians may never encounter it in their careers.
ResearchPUBMEDMar 26
A 45-year-old man had ear canal swelling and an ear infection that wouldn't go away with normal treatment. Doctors performed surgery but didn't find the cause at first. After more testing, they discovered the real problem: cancer cells from a blood disease called acute myeloid leukemia (AML) had come back and were growing in the bone behind his ear.
WHY IT MATTERSThis case shows that persistent ear infections that don't respond to standard treatment could be a sign of leukemia relapse, meaning AML patients with unusual ear symptoms need urgent investigation beyond typical infection treatment.
ResearchPUBMEDMar 26
Researchers studied how cancer tumors respond differently to a two-drug immunotherapy treatment (ipilimumab plus nivolumab) in patients with rare cancers. Some patients had some tumors shrink while others grew at the same time—called 'mixed response.' This study looked at 438 patients to understand how this mixed response affects how long patients survive and whether the cancer comes back.
WHY IT MATTERSUnderstanding mixed response patterns helps doctors better predict which rare cancer patients will benefit most from dual checkpoint inhibitor therapy and may improve how treatment success is measured beyond just tumor size.
ResearchPUBMEDMar 26
Scientists studying a rare childhood cancer called alveolar rhabdomyosarcoma have discovered how cancer cells make extra copies of certain genes that help them grow. They found that different parts of chromosomes (the structures that hold our genes) get copied in different ways—some amplify just one gene, while others amplify multiple genes at once. Understanding these patterns helps doctors figure out which patients might need different treatments.
WHY IT MATTERSThis research identifies specific genetic changes in rhabdomyosarcoma that could lead to targeted treatments tailored to each patient's tumor genetics, potentially improving survival rates for children with this aggressive cancer.
Clinical trialCLINICALTRIALSMar 26
Researchers at Emory University are testing a new combination of medicines for children whose cancer has come back or stopped responding to previous treatments. The study combines three drugs: sirolimus (which slows cell growth), celecoxib (an anti-inflammatory), and two chemotherapy drugs given in low doses. The goal is to see if this combination works better than standard treatments for solid tumors and brain cancers in children.
WHY IT MATTERSThis trial offers a potential new treatment option for children with recurrent or refractory cancers who have limited alternatives, though enrollment is currently closed.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a combination of two immunotherapy drugs in patients with four types of rare cancers: neuroendocrine tumors, biliary tract cancers, ovarian clear cell carcinoma, and tumors with high microsatellite instability. This Phase 2 trial involves 240 patients and is based on earlier research showing these cancers may respond well to this type of treatment.
WHY IT MATTERSPatients with these rare cancers now have access to a targeted immunotherapy combination that showed promise in earlier studies, potentially offering a new treatment option for cancers that historically have limited therapeutic choices.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a new cancer treatment called CART19 for children and young adults with specific types of blood cancer (B-ALL). The treatment uses the patient's own immune cells that are modified in a lab to fight cancer cells. This trial is looking for patients with rare, high-risk forms of this cancer, including some cases that have come back after previous treatment.
WHY IT MATTERSThis trial is actively recruiting children and young adults with hard-to-treat B-ALL subtypes (hypodiploid, t(17;19), KMT2A, and CNS relapse cases) — these patients have limited treatment options and this study offers access to an advanced cell therapy approach.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a new cancer drug called CLR 131 in children and young adults whose cancers have come back or stopped responding to standard treatments. The study includes kids with several types of hard-to-treat cancers like neuroblastoma, sarcomas, and brain tumors. This is an early-stage study to figure out the right dose and see if the drug is safe and effective.
WHY IT MATTERSThis trial offers a potential treatment option for children with relapsed or refractory neuroblastoma, sarcomas, and other pediatric solid tumors where standard treatments have failed—conditions with very limited curative options.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a new experimental cancer treatment called BNT326 to see if it is safe and works well for people with advanced solid tumors (cancers that have spread or come back after treatment). The study will first test BNT326 alone, then test it combined with other experimental treatments. About 980 people will participate in this Phase 1 and Phase 2 trial.
WHY IT MATTERSThis trial is actively recruiting patients with advanced solid tumors across multiple sites, offering access to a novel immunotherapy approach from BioNTech before it becomes widely available.
Clinical trialCLINICALTRIALSMar 26
Researchers completed a study testing two cancer drugs given together: imatinib mesylate and cyclophosphamide. The study involved 26 patients and aimed to find the safest and most effective dose of imatinib mesylate when combined with a fixed dose of cyclophosphamide. This was an early-stage study (Phase 1) to understand how these drugs work together in the body.
WHY IT MATTERSThis completed trial provides important safety and dosing information for doctors considering combination therapy with imatinib and cyclophosphamide for certain cancer patients, potentially improving treatment options.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a new drug called furmonertinib in patients with advanced lung cancer that has specific genetic mutations. This is an early-stage study (Phase 1) with 160 patients to see if the drug is safe and how well it works. The drug targets uncommon mutations in EGFR and HER2 genes that some lung cancer patients have.
WHY IT MATTERSThis trial addresses treatment options for patients with advanced NSCLC carrying uncommon EGFR or HER2 mutations, which typically have fewer targeted therapy options than common mutations.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing whether two cancer-fighting drugs called atezolizumab and bevacizumab work better together for treating rare cancers. These drugs help the body's immune system recognize and attack cancer cells. The study includes 133 patients with various uncommon solid tumors and is currently enrolling participants.
WHY IT MATTERSThis trial offers patients with rare cancers like Merkel cell carcinoma, nasopharyngeal cancer, and mesothelioma access to a combination immunotherapy treatment that may not be available outside of clinical research.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a new drug called zipalertinib to treat advanced lung cancer in patients who have a specific genetic mutation called EGFR exon 20 insertion. This mutation makes lung cancer harder to treat with standard medications. The study is looking for 220 patients to see if zipalertinib is safe and effective for this type of cancer.
WHY IT MATTERSThis trial targets EGFR exon 20 insertion mutations in advanced NSCLC, a genetic subtype that historically has limited treatment options and poor response to standard EGFR inhibitors.
ResearchCLINICALTRIALSMar 26
Researchers are studying 1,000 children and adults with adrenocortical carcinoma (ACC), a rare cancer of the adrenal glands. They want to understand why some people survive longer than others and whether certain treatments work better. The average person with ACC lives about 14.5 months after diagnosis, but survival times vary widely.
WHY IT MATTERSThis study is actively collecting data that could help doctors better predict outcomes and choose more effective treatments for ACC patients, though it is not currently recruiting new participants.